Recent Updates
Recently added Catalysts

Immune checkpoint inhibitors or docetaxel

Phase 3

Nonsmall Cell Lung Cancer | Small molecule | Oncology |NovoCure Limited|Last Updated: Mar 18, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment291

FDA Designations

No designations recorded

Clinical trial landscape

Immune checkpoint inhibitors or docetaxel · 1 trial · 2 indications

Phase 3 1
NCT02973789Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)Nonsmall Cell Lung Cancer
COMPLETED291 Analytics
PHASE3COMPLETED
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
Nonsmall Cell Lung Cancer
NCT02973789291
Unlock trial analytics

Study Endpoints

Primary Endpoints

Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 10.0 months).

Secondary Endpoints

Overall Survival of Patients Treated With TTFields + Immune Checkpoint Inhibitors vs. Immune Checkpoint Inhibitors Alone (Superiority)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 10.6 months).
Overall Survival of Patients Treated With TTFields + Docetaxel vs. Docetaxel Alone (Superiority Analysis)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 9.7 months).
Overall Survival of Patients Treated With TTFields + Docetaxel Vs. Immune Checkpoint Inhibitors Alone (Non-inferiority Analysis)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled. (median duration of follow-up was 10.1 months)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NovoTTF-200TEXPERIMENTALPatients receive TTFields using the NovoTTF-200T device together with immune checkpoint inhibitors or docetaxel
Best Standard of CareACTIVE_COMPARATORPatients receive best standard of care with immune checkpoint inhibitors or docetaxel

Interventions

NameTypeDescription
NovoTTF-200TDEVICEPatients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine. Other Name: TTFields Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Immune checkpoint inhibitors or docetaxelDRUGPatients receive standard of care with Immune checkpoint inhibitors or docetaxel
Unlock Study Design Details

Eligibility Criteria

Age Range22 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites124

Inclusion Criteria: 1. 22 years of age and older (some regional variations to inclusion age exist) 2. Life expectancy of ≥ 3 months 3. Histological diagnosis of squamous or non-squamous, inoperable, metastatic NSCLC 4. Diagnosis of radiological progression while on or after first platinum-based sys...

Countries:United StatesAustriaBelgiumBulgariaCanadaChinaCroatiaCzechiaFranceGermanyHong KongHungaryItalyNetherlandsPolandSerbiaSpainSwitzerland
Unlock Eligibility Criteria

Frequently asked questions about Immune checkpoint inhibitors or docetaxel

What is Immune checkpoint inhibitors or docetaxel used for?

Immune checkpoint inhibitors or docetaxel is being studied for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. It is part of a Phase 3 clinical trial evaluating its use in this patient population.

Who makes Immune checkpoint inhibitors or docetaxel?

Immune checkpoint inhibitors or docetaxel is being developed by NovoCure Limited, a company traded on the NASDAQ under the ticker symbol NVCR.

What phase is Immune checkpoint inhibitors or docetaxel in?

Immune checkpoint inhibitors or docetaxel is in Phase 3 clinical development. It is an investigational therapy and has not been approved by regulatory authorities for the treatment of non-small cell lung cancer.

What clinical trials is Immune checkpoint inhibitors or docetaxel in?

Immune checkpoint inhibitors or docetaxel is being evaluated in the LUNAR trial (NCT02973789), a Phase 3 study of Tumor Treating Fields (TTFields) at 150 kHz concurrent with standard of care therapies for stage 4 non-small cell lung cancer following platinum failure. The trial enrolled 291 participants and has been completed.

Is Immune checkpoint inhibitors or docetaxel the same as Tumor Treating Fields?

Immune checkpoint inhibitors or docetaxel is a treatment arm in the LUNAR trial, which evaluates Tumor Treating Fields (TTFields) at 150 kHz given concurrently with standard of care therapies, which include immune checkpoint inhibitors or docetaxel. The trial compares TTFields plus these therapies against the therapies alone.